

**DATES:** 8:00 a.m.–6:00 p.m., EST, February 24, 2016

**ADDRESSES:** CDC, Tom Harkin Global Communications Center, 1600 Clifton Road NE., Building 19, Kent “Oz” Nelson Auditorium, Atlanta, Georgia 30329.

**Status:** Open to the public, limited only by the space available. Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below by February 15, 2016. All requests must contain the name, address, and organizational affiliation of the speaker, as well as the topic being addressed. Written comments should not exceed one single-spaced typed page in length and delivered in 3 minutes or less. Please note that the public comment period may end before the time indicated, following the last call for comments. Members of the public who wish to provide public comments should plan to attend the public comment session at the start time listed. Written comments received in advance of the meeting will be included in the official record of the meeting.

The meeting will be webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP Web site: <http://www.cdc.gov/vaccines/acip/index.html>.

**Purpose:** The committee is charged with advising the Director, CDC, on the appropriate use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines. Further, under provisions of the Affordable Care Act, at section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been adopted by the Director of the Centers for Disease Control and Prevention and appear on the CDC immunization schedules must be covered by applicable health plans.

**Matters for Discussion:** The agenda will include discussions on: Meningococcal vaccines; human papillomavirus vaccines; influenza; hexavalent vaccine (DTaP–IPV–Hib–HepB); cholera vaccine; Japanese encephalitis vaccine; and vaccine supply. A recommendation vote is scheduled for influenza. A Vaccines for Children (VFC) vote is scheduled for

hexavalent vaccine (diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP)—inactivated polio vaccine (IPV)—Haemophilus influenzae type b (Hib)—hepatitis B (HepB).

Agenda items are subject to change as priorities dictate.

**FOR FURTHER INFORMATION CONTACT:**

Stephanie Thomas, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road NE., MS–A27, Atlanta, Georgia 30329, telephone 404–639–8836; Email [ACIP@CDC.GOV](mailto:ACIP@CDC.GOV).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2016–02080 Filed 2–3–16; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Initial Review

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to Funding Opportunity Announcement (FOA) PAR 15–303, Occupational Safety and Health Education and Research Centers (ERC).

**DATES:** 6:00 p.m.–8:00 p.m., February 22, 2016 (Closed)

7:00 a.m.–6:00 p.m., February 23, 2016 (Closed)

7:00 a.m.–6:00 p.m., February 24, 2016 (Closed)

**ADDRESSES:** Hilton Alexandria Old Town, 1767 King Street, Alexandria, Virginia 22314, Telephone: (703) 837–0440.

**Status:** The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

**Matters for Discussion:** The meeting will include the initial review, discussion, and evaluation of applications received in response to “Occupational Safety and Health Education and Research Centers (ERC),” PAR 15–303.

**FOR FURTHER INFORMATION CONTACT:**

George Bockosh, M.S., Scientific Review Officer, CDC, NIOSH, 2400 Century Center Parkway NE., 4th Floor, Mailstop E–74, Atlanta, Georgia 30345, Telephone: (412) 386–6465, [GGB0@CDC.GOV](mailto:GGB0@CDC.GOV) and Donald Blackman, Ph.D., Scientific Review Officer, CDC, NIOSH, 2400 Century Center Parkway NE., 4th Floor, Room 4204, Mailstop E–74, Atlanta, Georgia 30345, Telephone: (404) 498–6185, [DYB7@CDC.GOV](mailto:DYB7@CDC.GOV).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2016–02079 Filed 2–3–16; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Subcommittee on Procedures Review (SPR), Advisory Board on Radiation and Worker Health, National Institute for Occupational Safety and Health Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting for the aforementioned subcommittee:

**DATES:** 11:00 a.m.–4:30 p.m., EST, February 24, 2016.

**ADDRESSES:** Audio Conference Call via FTS Conferencing.

**Status:** Open to the public, but without a public comment period. The public is welcome to submit written comments in advance of the meeting, to the contact person below. Written comments received in advance of the meeting will be included in the official record of the meeting. The public is also welcome to listen to the meeting by joining the teleconference at the USA

toll-free, dial-in number at 1-866-659-0537 and the pass code is 9933701.

**Background:** The Advisory Board on Radiation and Worker Health (ABRWH or the Advisory Board) was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Advisory Board include providing advice on the development of probability of causation guidelines that have been promulgated by the Department of Health and Human Services (HHS) as a final rule; advice on methods of dose reconstruction, which have also been promulgated by HHS as a final rule; advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program; and advice on petitions to add classes of workers to the Special Exposure Cohort.

In December 2000, the President delegated responsibility for funding, staffing, and operating the Advisory Board to HHS, which subsequently delegated this authority to CDC. National Institute for Occupational Safety and Health (NIOSH) implements this responsibility for CDC. The charter was issued on August 3, 2001, renewed at appropriate intervals, and will expire on August 3, 2017.

**Purpose:** The Advisory Board is charged with (a) providing advice to the Secretary, HHS, on the development of guidelines under Executive Order 13179; (b) providing advice to the Secretary, HHS, on the scientific validity and quality of dose reconstruction efforts performed for this program; and (c) upon request by the Secretary, HHS, advise the Secretary on whether there is a class of employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is reasonable likelihood that such radiation doses may have endangered the health of members of this class. SPR was established to aid the Advisory Board in carrying out its duty to advise the Secretary, HHS, on dose reconstruction. SPR is responsible for overseeing, tracking, and participating in the reviews of all procedures used in the dose reconstruction process by the NIOSH Division of Compensation Analysis and Support (DCAS) and its dose reconstruction contractor (Oak Ridge Associated Universities—ORAU).

**Matters for Discussion:** The agenda for the Subcommittee meeting includes

discussion of procedures in the following ORAU and DCAS technical documents: OCAS Technical Information Bulletin (TIB) 0014 (“Rocky Flats Internal Dosimetry Coworker Extension”), ORAU OTIB 0013 (“Individual Dose Adjustment Procedures for Y-12 Dose Reconstructions”), ORAU OTIB 0029 (“Internal Dose Reconstructions for Y-12”), ORAU OTIB 0039 (“Internal Dose Reconstructions for Hanford”), ORAU OTIB 0050 (“The Use of Rocky Flats Neutron Dose Reconstruction Project Data in Dose Reconstructions”), ORAU OTIB 0060 (“Internal Dose Reconstructions”), Program Evaluation Report (PER) 003 (“The Effects of Adding Ingestion Intakes to Bethlehem Steel Cases”), PER 004 (“Application of Photofluorography at the Pinellas Plant”), PER 005 (“Misinterpreted Application of External Dose Factor for Hanford Dose Reconstructions”), PER 029 (“Hanford TBD Revision”), PER 042 (“Linde Ceramic Plant TBD Revision”), PER 045 (“Aliquippa Forge TBD Revision”), ORAU PROC 0042 (“Incomplete Monitoring at Y-12”), ORAU RPRT 0044 (“Analysis of Bioassay Data with Significant Fraction of Less-Than Results”); and a continuation of the comment-resolution process for other dose reconstruction procedures under review by the Subcommittee.

The agenda is subject to change as priorities dictate.

**FOR FURTHER INFORMATION CONTACT:**

Theodore Katz, Designated Federal Officer, NIOSH, CDC, 1600 Clifton Road NE., Mailstop E-20, Atlanta, Georgia 30333, Telephone (513) 533-6800, Toll Free 1(800) CDC-INFO, Email [ocas@cdc.gov](mailto:ocas@cdc.gov).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2016-02081 Filed 2-3-16; 8:45 am]

**BILLING CODE 4163-19-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Request for Nominations of Candidates To Serve on the Interagency Committee on Smoking and Health, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS)**

The CDC is soliciting nominations for possible membership on the Interagency Committee on Smoking and Health (ICSH), Office on Smoking and Health (OSH).

The ICSH consists of five members appointed by the Secretary from physicians and scientists who represent private entities involved in informing the public about the health effects of smoking. The members are selected by the Secretary, HHS. The committee provides advice and guidance to the Secretary, HHS, and the Director, CDC regarding (a) coordination of all research and education programs and other activities within the Department and with other Federal, State, local and private agencies and (b) establishment and maintenance of liaison with appropriate private entities, Federal agencies, and State and local public health agencies with respect to smoking and health activities.

Nominations are being sought for individuals who have expertise and qualifications necessary to contribute to the accomplishment of the committee's objectives. More information is available on the ICSH, OSH Web site: <http://www.cdc.gov/tobacco/ICSH/index.htm>.

Nominees will be selected based on expertise in the field of tobacco control and multi-disciplinary expertise in public health. Additionally, desirable qualifications include: (1) Knowledge of emerging tobacco control policies and experience in analyzing, evaluating, and interpreting Federal, State and/or local health or regulatory policy; or (2) knowledge of emerging tobacco products and the evolving environment of tobacco control and expertise in developing or contributing to the development of policies and/or programs; or (3) familiarity of rapid and emerging surveillance systems that will allow for the timely evaluation of tobacco product regulation and/or the impact of tobacco control interventions.

Federal employees will not be considered for membership.

Members may be invited to serve for terms of up to four years. The U.S. Department of Health and Human